武汉回盛生物科技股份有限公司 关于向特定对象发行股票的审核问询函回复 及募集说明书等申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300871 证券简称：回盛生物 公告编号：2025-079 公司会同相关中介机构对《审核问询函》所提出的问题进行了认真研究和 落实后，对《审核问询函》所列问题进行了逐项说明和回复，同时对募集说明 书等申请文件的内容进行了更新。同时，鉴于公司已于近日披露了《2025 年半 年度报告》，公司会同相关中介机构对募集说明书等申请文件中涉及的财务数 据及其他变动事项进行了同步更新。具体内容详见公司于 2025 年 8 月 15 日在 巨潮资讯网（www.cninfo.com.cn）上披露的相关公告文件。 公司本次向特定对象发行股票事项尚需通过深交所上市审核中心审核，并 获得中国证券监督管理委员会（以下简称"中国证监会"）同意注册后方可实 施，最终能否通过深交所审核，并获得中国证监会同意注册的决定及时间尚存 在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大 投资者注意投资风险。 特此公 ...

证券简称：回盛生物 证券代码：300871 武汉回盛生物科技股份有限公司 Wuhan Hvsen Biotechnology Co.,Ltd. （武汉市东西湖区张柏路218号） 向特定对象发行A股股票 募集说明书 （申报稿） 保荐人（主承销商） 签署日期：二〇二五年八月 武汉回盛生物科技股份有限公司 向特定对象发行A股股票募集说明书 声 明 本公司及全体董事、监事、高级管理人员、控股股东及实际控制人承诺本募集 说明书及其他信息披露资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其 真实性、准确性及完整性承担相应的法律责任。 本公司负责人、主管会计工作负责人及会计机构负责人保证本募集说明书中财 务会计资料真实、完整。 中国证券监督管理委员会、深圳证券交易所对本次发行所做的任何决定或意见， 均不表明其对申请文件及所披露信息的真实性、准确性、完整性做出保证，也不表 明其对本公司的盈利能力、投资价值或者对投资者的收益做出实质性判断或保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发行 人自行负责。投资者自主判断发行人的投资价值，自主做出投资决策，自行承担 ...

中信建投证券股份有限公司 关于 武汉回盛生物科技股份有限公司 向特定对象发行股票 之 上市保荐书 保荐人 二〇二五年八月 保荐人出具的上市保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人陈子晗、张兴华已根据《中 华人民共和国公司法》《中华人民共和国证券法》等法律法规和中国证监会及深 圳证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则 和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 3-3-1 | 释 义 4 | | --- | | 一、发行人基本情况 6 | | （一）发行人概况 6 | | （二）发行人主营业务 6 | | （三）发行人主要经营和财务数据及指标 6 | | （四）发行人存在的主要风险 8 | | 二、发行人本次发行情况 14 | | （一）发行股票的种类和面值 14 | | （二）发行方式及发行时间 14 | | （三）发行对象及认购方式 14 | | （四）发行价格及定价原则 15 | | （五）发行数量 15 | | （六）限售期 16 | | （七）募集资金金额与用途 16 | | （八）本次向特定对象发行前公司滚存未分配 ...

武汉回盛生物科技股份有限公司 向特定对象发行股票 之 中信建投证券股份有限公司 关于 保荐人 二〇二五年八月 保荐人出具的证券发行保荐书 发行保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人陈子晗、张兴华根据《中华 人民共和国公司法》《中华人民共和国证券法》等有关法律、法规和中国证监会 的有关规定以及深圳证券交易所的有关业务规则，诚实守信，勤勉尽责，严格按 照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书，并保证发 行保荐书的真实性、准确性和完整性。 3-1-1 | 释 义 3 | | --- | | 第一节 本次证券发行基本情况 5 | | 一、本次证券发行具体负责推荐的保荐代表人 5 | | 二、本次证券发行项目协办人及项目组其他成员 5 | | 三、发行人基本情况 7 | | 四、保荐人与发行人关联关系的说明 10 | | 五、保荐人内部审核程序和内核意见 11 | | 六、保荐人对私募投资基金备案情况的核查 13 | | 第二节 保荐人承诺事项 14 | | 第三节 关于有偿聘请第三方机构和个人等相关行为的核查 15 | | 一、本保荐人有偿聘请第三方等相关行为的 ...

关于武汉回盛生物科技股份有限公司 申请向特定对象发行股票的审核问询函之回复报告 众环专字（2025）0101322 号 深圳证券交易所： 根据贵所于 2025 年 7 月 25 日出具的《关于武汉回盛生物科技股份有限公司申请向特定 对象发行股票的审核问询函》（以下简称"问询函"）的要求，中审众环会计师事务所（特殊 普通合伙）（以下简称"会计师"或"中审众环"）作为武汉回盛生物科技股份有限公司（以 下简称"发行人"、"公司"、"回盛生物"）的审计机构（于 2023 年、2024 年及 2025 分别出 具了（众环审字（2023）0102044 号、众环审字（2024）0102244 号、众环审字（2025）0102563 号无保留意见审计报告，2025 年 1-6 月的数据未经审计）已会同发行保荐人和律师，对问 询函所列相关问题逐项进行了认真核查，现对问询函回复如下，请审核。 问题 1 根据申报材料，公司以猪用药品为核心，主要包括兽用化药制剂、兽用原料药和兽用中 药制剂三大产品类别。报告期内，发行人营业收入分别为 102,290.08 万元、101,975.88 万元、 120,032.79 万元和 39,90 ...

Core Insights - The animal health sector experienced a significant increase of 3.86% on August 15, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Stock Performance - Shenlian Biological (688088) saw a closing price of 10.69, with a remarkable increase of 19.98% and a trading volume of 435,300 shares, amounting to a transaction value of 441 million yuan [1] - Other notable performers included: - Biological Shares (600201) with a closing price of 8.93, up 6.06% [1] - Ruipu Biological (300119) with a closing price of 22.78, up 5.56% [1] - KQ Biological (688526) with a closing price of 17.24, up 2.44% [1] Capital Flow - The animal health sector saw a net inflow of 49.48 million yuan from institutional investors, while retail investors contributed a net inflow of 40.08 million yuan [1] - Notably, retail funds experienced a net outflow of 89.56 million yuan [1] Detailed Capital Flow Analysis - Shenlian Biological had a net inflow of 54.78 million yuan from institutional investors, while it faced a net outflow of 41.10 million yuan from speculative funds [2] - Biological Shares had a net inflow of 14.26 million yuan from institutional investors, with a net outflow of 33.08 million yuan from speculative funds [2] - Ruipu Biological recorded a net inflow of 1.78 million yuan from institutional investors, while speculative funds saw a net outflow of 16.93 million yuan [2]

Investment Rating - The report does not explicitly state an investment rating for the animal health industry, but it highlights potential growth areas such as pet pharmaceuticals and international expansion [1]. Core Insights - The animal health industry is experiencing a slowdown in growth, with increasing competition leading to a "Matthew Effect" where larger companies gain more market share at the expense of smaller firms [3][39]. - The industry is shifting back to a research and development-driven model, with innovation becoming crucial for future growth [4][83]. - The pet pharmaceutical market and international expansion are identified as key areas for long-term growth, with pet medical consumption projected to reach approximately 84 billion yuan in 2024 [5][78]. Summary by Sections 1. Overview of the Animal Health Industry - The animal health industry, also known as the veterinary drug industry, includes a wide range of products such as vaccines, antibiotics, and feed additives [11][12]. - The market size has grown from 50.395 billion yuan in 2019 to 69.651 billion yuan in 2023, with a CAGR of 8.43% [3][12]. 2. Increasing Competition and Market Dynamics - The industry is facing a slowdown in growth, with sales increasing from 62.095 billion yuan in 2020 to 69.651 billion yuan in 2023, while average gross profit has decreased from 21.998 billion yuan to 21.297 billion yuan [3][39]. - The "Matthew Effect" is evident as larger companies leverage their product portfolios and R&D investments to capture more market share [3][52]. 3. Shift Towards R&D and Innovation - The industry is moving away from its cyclical nature, with a focus on integrated strategies and innovation to counteract competitive pressures [4][69]. - The average profit per head in self-breeding pig farming is expected to improve significantly in 2024, indicating potential for recovery in related sectors [4][62]. 4. Growth Opportunities in Pet Pharmaceuticals and Exports - The pet medical market is projected to grow rapidly, with a significant increase in demand for preventive care and treatment as pet owners become more health-conscious [5][78]. - The report highlights the successful export of domestic pet pharmaceuticals, marking a breakthrough in international markets [5][78]. 5. Key Companies to Watch - Companies such as 瑞普生物 (Reap Bio), 科前生物 (KQ Bio), and 回盛生物 (Hui Sheng Bio) are recommended for attention due to their innovative approaches and market positioning [6].

Market Overview - The animal health sector experienced a decline of 0.53% on August 13, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - Key stocks in the animal health sector showed varied performance, with Xianfeng Holdings closing at 3.78, up 0.53%, and Dayu Biological closing at 9.84, down 3.15% [2][1] - Other notable stocks included Jinhe Biological at 7.45, down 3.12%, and Zhongmu Co. at 7.56, down 0.66% [2][1] Trading Volume and Value - The trading volume for Xianfeng Holdings was 268,700 shares with a transaction value of 102 million yuan, while Dayu Biological had a trading volume of 46,200 shares and a transaction value of 45.92 million yuan [2][1] Capital Flow Analysis - The animal health sector saw a net outflow of 175 million yuan from institutional investors, while retail investors contributed a net inflow of 143 million yuan [2][3] - The capital flow for specific stocks indicated that Hai Li Biological had a net inflow of 2.28 million yuan from institutional investors, while Xianfeng Holdings experienced a significant net outflow of 11.02 million yuan [3][2]

Core Viewpoint - The announcement by Huisheng Biological indicates the approval of "Penicillin V Potassium Soluble Powder" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China, which is a significant milestone for the company and the veterinary pharmaceutical industry [1] Group 1 - The Ministry of Agriculture and Rural Affairs approved the joint application for the new veterinary drug on August 7, 2025 [1] - The approval is in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The issuance of the New Veterinary Drug Registration Certificate (Announcement No. 935) marks a regulatory achievement for the company [1]

Group 1 - The core point of the article is that Huisheng Biological has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its new veterinary drug, "Penicillin V Potassium Soluble Powder" [1] - The approval was granted based on the regulations of the Veterinary Drug Management and Veterinary Drug Registration [1] - The new veterinary drug registration certificate was issued on August 7, 2025 [1]